Spectrum of acute renal failure in the intensive care unit: the PICARD experience.

BACKGROUND Acute renal failure (ARF) in the critically ill is associated with extremely high mortality rates. Understanding the changing spectrum of ARF will be necessary to facilitate quality improvement efforts and to design successful interventional trials. METHODS We conducted an observational cohort study of 618 patients with ARF in intensive care units at five academic medical centers in the United States. Participants were required to sign (or have a proxy sign) informed consent for data collection. A comprehensive data collection instrument captured more than 800 variables, most on a daily basis, throughout the course of ARF. Patient characteristics, dialysis status, and major outcomes were determined and stratified by clinical site. RESULTS The mean age was 59.5 years, 41% were women, and 20% were of minority race or ethnicity. There was extensive comorbidity; 30% had chronic kidney disease, 37% had coronary artery disease, 29% had diabetes mellitus, and 21% had chronic liver disease. Acute renal failure was accompanied by extrarenal organ system failure in most patients, even those who did not require dialysis. Three hundred and ninety-eight (64%) patients required dialysis. The in-hospital mortality rate was 37%, and the rate of mortality or nonrecovery of renal function was 50%. The median hospital length of stay was 25 days (26 days, excluding patients who died). CONCLUSION There is a changing spectrum of ARF in the critically ill, characterized by a large burden of comorbid disease and extensive extrarenal complications, obligating the need for dialysis in the majority of patients. There is wide variation across institutions in patient characteristics and practice patterns. These differences highlight the need for additional multicenter observational and interventional studies in ARF.

[1]  T. Ikizler,et al.  Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  D. Feller-Kopman,et al.  Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  R. Kaplan,et al.  Nephrology consultation in acute renal failure: does timing matter? , 2002, The American journal of medicine.

[4]  John P. Johnson,et al.  Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. , 2002, Kidney international.

[5]  J. le Gall,et al.  Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients* , 2002, Critical care medicine.

[6]  G. Prescott,et al.  Acute renal failure requiring renal replacement therapy: incidence and outcome. , 2002, QJM : monthly journal of the Association of Physicians.

[7]  C. Guérin,et al.  Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: results from a multicenter prospective epidemiological survey , 2002, Intensive Care Medicine.

[8]  F. Luft,et al.  Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  G. Chertow,et al.  Refining predictive models in critically ill patients with acute renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[10]  R. Bellomo,et al.  Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia , 2001, Critical care medicine.

[11]  R. Kaplan,et al.  A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. , 2001, Kidney international.

[12]  E. Baulieu,et al.  Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  D. Bates,et al.  Mortality and costs of acute renal failure associated with amphotericin B therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Cummings,et al.  A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  M. Coco,et al.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. Lewis,et al.  Atrial natriuretic factor in oliguric acute renal failure , 2000 .

[17]  C. Sprung,et al.  Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score , 2000, Intensive Care Medicine.

[18]  M. Giustini,et al.  Urinary Deoxypyridinoline Excretion for the Evaluation of Bone Turnover in Chronic Renal Failure , 2000, American Journal of Nephrology.

[19]  Craig S. Wong,et al.  Increased risk of hip fracture among patients with end-stage renal disease. , 2000, Kidney international.

[20]  D W Bates,et al.  Predicting acute renal failure after coronary bypass surgery: cross-validation of two risk-stratification algorithms. , 2000, Kidney international.

[21]  C. Guérin,et al.  Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Rhône-Alpes Area Study Group on Acute Renal Failure. , 2000, American journal of respiratory and critical care medicine.

[22]  S. Miller,et al.  Acute renal failure in the cardiac care unit: etiologies, outcomes, and prognostic factors. , 1999, Kidney international.

[23]  Roger A. Kaiser,et al.  Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. , 1999, Kidney international.

[24]  J. Achard,et al.  Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? , 1999, Kidney international.

[25]  E. Fiaccadori,et al.  Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: a prospective cohort study. , 1999, Journal of the American Society of Nephrology : JASN.

[26]  M. Emoto,et al.  Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. , 1999, Kidney international.

[27]  E. Bonucci,et al.  Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  J. Pascual,et al.  Outcomes in acute renal failure. , 1998, Seminars in nephrology.

[29]  J Pascual,et al.  The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. , 1998, Kidney international. Supplement.

[30]  R. Lafayette,et al.  Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. , 1998, Journal of the American Society of Nephrology : JASN.

[31]  R. Lafayette,et al.  Anaritide in Acute Tubular Necrosis , 1997 .

[32]  J Pascual,et al.  Epidemiology of acute renal failure: A prospective, multicenter, community-based study , 1996 .

[33]  G. Chertow,et al.  Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. , 1996, The American journal of medicine.

[34]  G. Chertow,et al.  "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. , 1996, Kidney international.

[35]  Hiroyuki Tanaka,et al.  24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice. , 1996, Endocrinology.

[36]  G. Liaño,et al.  Acute renal failure. Madrid Acute Renal Failure Study Group. , 1996, Lancet.

[37]  Paul Landais,et al.  Acute renal failure in intensive care units : causes, outcome, and prognostic factors of hospital mortality : a prospective, multicenter study , 1996 .

[38]  P. Loirat,et al.  Acute renal failure in intensive care units--causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. , 1996, Critical care medicine.

[39]  J. McCarthy Prognosis of patients with acute renal failure in the intensive-care unit: a tale of two eras. , 1996, Mayo Clinic proceedings.

[40]  P. Loirat,et al.  Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  C. Christiansen,et al.  Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. , 1995, Archives of internal medicine.

[42]  E. Ogata,et al.  Effect of 24R,25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells , 1993, Calcified Tissue International.

[43]  E. Bonucci,et al.  Bone histomorphometric reference values in 88 normal Italian subjects. , 1990, Bone and mineral.

[44]  B. Hollis,et al.  Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. , 1990, The Journal of clinical endocrinology and metabolism.

[45]  H. Malluche,et al.  Renal bone disease 1990: an unmet challenge for the nephrologist. , 1990, Kidney international.

[46]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[47]  B. Halloran,et al.  Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. , 1984, The Journal of clinical endocrinology and metabolism.

[48]  J. Cohen,et al.  Hospital-acquired renal insufficiency: a prospective study. , 1983, The American journal of medicine.

[49]  J. Eastwood,et al.  VITAMIN-D DEFICIENCY IN THE OSTEOMALACIA OF CHRONIC RENAL FAILURE , 1976, The Lancet.

[50]  G. Delling,et al.  Immunoreaktives Parathormon, 25-Hydroxycalciferol und Knochenhistologie bei renaler Osteopathie , 1976, Klinische Wochenschrift.

[51]  P. Jungers,et al.  Uremic and non-uremic complications in acute renal failure: Evaluation of early and frequent dialysis on prognosis. , 1972, Kidney international.

[52]  G. Chertow,et al.  Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  R. Lafayette,et al.  Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. , 1997, The New England journal of medicine.

[54]  J. Delmez,et al.  Extrarenal production of calcitriol in normal and uremic humans. , 1991, The Journal of clinical endocrinology and metabolism.

[55]  A K Mortagy,et al.  Risk factors and outcome of hospital-acquired acute renal failure (clinical epidemiologic study). , 1988, The Journal of the Egyptian Public Health Association.